GLP-1R agonist use was associated with a reduced risk of hypocalcemia (2.7% vs. 5.5%, p < 0.001; RR 0.49, 95% CI: 0.44–0.55) and improved clinical outcomes, particularly in cardiovascular health. Here, GLP1R is linked to Hypocalcemia.